Key result
SRT1720 treatment improved cardiac function and attenuated deleterious left ventricular remodeling in a mouse model of pressure overload.
Why the study?
Does pharmacological activation of SIRT1 with SRT1720 attenuate cardiac fibrosis and improve cardiac function in a rodent pressure overload model?
RCT
randomized
Does pharmacological activation of SIRT1 with SRT1720 attenuate cardiac fibrosis and improve cardiac function in a rodent pressure overload model?
Pharmacological activation of SIRT1 with SRT1720 attenuates cardiac fibrosis and improves cardiac function in a mouse model of pressure overload, suggesting a potential therapeutic strategy for heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for SIRT1 activation in HF; leaves open clinical translation from rodent pressure-overload models.
Aims: Transforming growth factor β1 (TGF-β1) is a prosclerotic cytokine involved in cardiac remodelling leading to heart failure (HF). Acetylation/de-acetylation of specific lysine residues in Smad2/3 has been shown to regulate TGF-β signalling by altering its transcriptional activity. Recently, the lysine de-acetylase sirtuin 1 (SIRT1) has been shown to have a cardioprotective effect; however, SIRT1 expression and activity are paradoxically reduced in HF. Herein, we investigate whether pharmacological activation of SIRT1 would induce cardioprotection in a pressure overload model and assess the impact of SIRT1 activation on TGF-β signalling and the fibrotic response. Methods and results: Eight weeks old male C57BL/6 mice were randomized to undergo sham surgery or transverse aortic constriction (TAC) to induce pressure overload. Post-surgery, animals were further randomized to receive SRT1720 or vehicle treatment. Echocardiography, pressure-volume loops, and histological analysis revealed an impairment in cardiac function and deleterious left ventricular remodelling in TAC-operated animals that was improved with SRT1720 treatment. Genetic ablation and cell culture studies using a Smad-binding response element revealed SIRT1 to be a specific target of SRT1720 and identified Smad2/3 as a SIRT1 specific substrate. Conclusion: Overall, our data demonstrate that Smad2/3 is a specific SIRT1 target and suggests that pharmacological activation of SIRT1 may be a novel therapeutic strategy to prevent/reverse HF via modifying Smad activity.
No takes yet. Share an insight, caveat, or question.
Bugyei‐Twum et al. (2018) conducted an RCT in Pressure overload / Heart failure. SRT1720 vs. Vehicle was evaluated on Cardiac function and left ventricular remodelling. SRT1720 treatment improved cardiac function and attenuated deleterious left ventricular remodeling in a mouse model of pressure overload.
Synapse has enriched 10 related papers. Consider them for comparative context: